EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Bre...( Results Demonstrate Dura...),Health

Results Demonstrate Durable Single Agent Responses

ROCKVILLE, Md., Sept. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results for its Phase 2 clinical study of MKC-1 in patients with metastatic breast cancer (MBC). The data were presented by EntreMed collaborators during the 2007 Breast Cancer Symposium "Integrating Emerging Science into Clinical Practice," held September 7-8, 2007 in San Francisco, California. Dr. Kathy D. Miller, Associate Professor, Indiana University Cancer Center, Indianapolis, Indiana is the first author.

The Phase 2 single-agent study is being conducted at multiple centers across the United States to evaluate the safety and efficacy of MKC-1 in metastatic breast cancer patients who have failed therapy with anthracyclines and taxanes. Results from the first stage of the single-agent study demonstrate that orally-administered MKC-1 is well-tolerated without evidence of cumulative toxicity in anthracycline/taxane refractory metastatic breast cancer patients. Of the 35 evaluable patients, one complete response (CR), two partial responses (PR), and three stable diseases (SD) of greater than four months were observed. This study has proceeded to the second stage and is continuing to enroll up to 53 evaluable patients to confirm safety and assess the extent of objective responses in this patient population.

MKC-1 is a novel, orally-active, small molecule cell cycle inhibitor with a unique mechanism of action, which involves inhibition of the Akt-mTOR pathway, binding importin-b and tubulin, cell cyc
'/>"/>